

February 3, 2015  
SymBio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director  
President and Chief Executive Officer

## **Onconova Announces its Clinical Development Plan for Rigosertib in MDS**

TOKYO, Japan, February 3, 2015 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio") announced today that US partner, Onconova Therapeutics, Inc. (Headquarters: Newtown, PA, "Onconova") announced plans for further clinical development of rigosertib in patients with myelodysplastic syndromes ("MDS") on February 2, 2015 (EST).

Given this announcement, SymBio will revisit its clinical development plan for rigosertib in Japan and South Korea after further consultation with Onconova.

For more details in this press release, please visit Onconova's homepage at  
<http://investor.onconova.com/releases.cfm>

### **[Contact]**

Investor Relations

Tel: +81(0)3 5472 1125

[Please read the following for more information Onconova, rigosertib and SymBio]

### **[Glossary]**

#### **About Onconova Therapeutics, Inc.**

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer. Onconova's clinical and pre-clinical stage drug development candidates are derived from its proprietary chemical library and are designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. In addition to rigosertib, the Company's most advanced product candidate under clinical development, two other drug candidates, briciclib and recilisib, are in clinical trials and several candidates are in pre-clinical development. For more information, please visit <http://www.onconova.com>.

#### **About SymBio Pharmaceuticals Limited**

SymBio Pharmaceuticals Ltd. was established in March, 2005, by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. The company's underlying corporate mission is "delivering hope to patients in need" as it aspires to be a leading specialty pharmaceutical company in Asia Pacific dedicated to addressing underserved medical needs with main focus in the areas of oncology, hematology and autoimmune disease.